Skip to Main Content

INFORMATION FOR

Examining the Effect of Burosumab on Muscle Function

Conditions

Diseases of the Musculoskeletal System

Phase COVID-NA

What is the purpose of this trial?

Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.

  • Trial with
    Yale University School of Medicine
  • Start Date
    02/13/2020
  • End Date
    09/30/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000026400